Chardan analyst Geulah Livshits raised the firm’s price target on Crispr Therapeutics (CRSP) to $76 from $74 and keeps a Buy rating on the shares following the Q4 report. The company company is continuing to expand its in vivo cardiovascular editing and siRNA franchises in addition to recent preclinical progress toward in vivo CAR-T capabilities, the analyst tells investors in a research note. Chardan updated Crispr’s model post the results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
- Crispr Therapeutics price target raised to $82 from $80 at Needham
- Crispr Therapeutics price target raised to $45 from $40 at TD Cowen
- CRISPR Therapeutics: Casgevy Outperformance and Advancing In Vivo Pipeline Underpin Buy Rating
- Crispr Therapeutics price target lowered to $86 from $89 at BofA